You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Addressing Suboptimal Anticoagulation in Atrial Fibrillation: Uncoupling the Potential of Factor XI/XIa Inhibition for Stroke Prevention

  • Authors: Marc S. Sabatine, MD, MPH; Jeffrey I. Weitz, MD, FRCP(C), FACP, FCCP; Christian T. Ruff, MD, MPH
  • CME / ABIM MOC / CE Released: 11/17/2023
  • Valid for credit through: 11/17/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    Nurses - 0.50 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

    Pharmacists - 0.50 Knowledge-based ACPE (0.050 CEUs)

    IPCE - 0.50 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for cardiologists, primary care providers, emergency medicine physicians, hematologists, nurses/nurse practitioners (NPs), physician assistants (PAs), pharmacists, and other health care professionals (HCPs) who care for patients with atrial fibrillation (AF).

The goal of this activity is for learners to be better able to identify trends and gaps in optimal stroke prevention in high-risk patients with AF, including the proportion of patients with AF who are not optimally treated (ie, undertreated, not treated, and/or mistreated), factors affecting suboptimal treatment, and evaluate the emerging role of factor XI/XIa inhibition for stroke prevention in patients with AF to address current limitations of standard of care (SOC) anticoagulation approaches.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Unmet treatment needs associated with achieving optimal stroke prevention with anticoagulation for patients with AF at risk of stroke
    • Role of factor XI/XIa inhibition for stroke prophylaxis in patients with AF to address current gaps in optimal anticoagulation
    • Emerging clinical trial evidence for the use of factor XI/XIa inhibition for stroke prevention in patients with AF
  • Demonstrate greater confidence in their ability to
    • Discern the value of emerging anticoagulation strategies targeting factor XI/XIa for stroke prevention in patients with AF as part of the interprofessional team 


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Moderator

  • Marc S. Sabatine, MD, MPH

    Chairman, TIMI Study Group 
    Lewis Dexter, MD
    Distinguished Chair in Cardiovascular Medicine
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts, United States

    Disclosures

    Marc S. Sabatine, MD, MPH, has the following relevant financial relationships: 
    Consultant or advisor for: Amgen Inc.; Anthos Therapeutics; AstraZeneca; Beren Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc.; Dr. Reddy’s Laboratories; FibroGen, Inc.; Intarcia Therapeutics, Inc.; Merck; Moderna, Inc.; Novo Nordisk; Precision BioSciences; Silence Therapeutics
    Research funding from: Abbott; Amgen Inc.; Anthos Therapeutics; ARCA Biopharma Inc.; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Intarcia Therapeutics, Inc.; Ionis Pharmaceuticals; Janssen Research and Development, LLC; Merck; Novartis; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Roche; Siemens Healthcare Diagnostics Inc.; Softcell Medical Limited; Zora Biosciences

Faculty

  • Jeffrey I. Weitz, MD, FRCP(C), FACP, FCCP

    Professor of Medicine and Biochemistry
    McMaster University
    Hamilton, Ontario, Canada

    Disclosures

    Jeffrey I. Weitz, MD, FRCP(C), FACP, FCCP, has no relevant financial relationships.

  • Christian T. Ruff, MD, MPH

    Associate Professor of Medicine
    Harvard Medical School
    Director of General Cardiology
    Brigham and Women's Hospital
    Senior Investigator, TIMI Study Group
    Boston, Massachusetts, United States

    Disclosures

    Christian T. Ruff, MD, MPH, has the following relevant financial relationships: 
    Consultant or advisor for: Anthos Therapeutics; Bayer; Bristol Myers Squibb Company; Daiichi Sankyo, Inc.; Janssen Biotech, Inc.; Pfizer, Inc.
    Research funding from: Anthos Therapeutics; AstraZeneca; Daiichi Sankyo, Inc.; Janssen Biotech, Inc.; Novartis

Editor

  • Asha P. Gupta, PharmD, RPh

    Medical Education Director, Medscape, LLC 

    Disclosures

    Asha P. Gupta, PharmD, RPh, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Maria Morales, MSN, RN, CLNC

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Maria Morales, MSN, RN, CLNC, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number: JA0007105-0000-23-387-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Addressing Suboptimal Anticoagulation in Atrial Fibrillation: Uncoupling the Potential of Factor XI/XIa Inhibition for Stroke Prevention

Authors: Marc S. Sabatine, MD, MPH; Jeffrey I. Weitz, MD, FRCP(C), FACP, FCCP; Christian T. Ruff, MD, MPHFaculty and Disclosures

CME / ABIM MOC / CE Released: 11/17/2023

Valid for credit through: 11/17/2024, 11:59 PM EST

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

  • Print